INDUSTRY INSIGHTS

• MHRA's 2026 Devices Reform: What Changes And When

  Great Britain’s draft medical device regulations realign requirements with EU MDR standards. Review transition timelines, technical document rules, and gap analysis strategies now.

• FDA's Risk-Based Inspection Shift: What It Actually Rewards

  FDA’s revised pre-approval inspection program prioritizes risk-based determinations over routine site visits. Review risk assessment factors and transition toward continuous audit readiness.

• What The FDA's AI Device Software Guidance Signals For Your Traceability

  FDA draft guidance sets lifecycle expectations for AI/ML medical device software. Review dataset provenance and post-market monitoring strategies to prepare your submissions.

• If Compliance Is Slowing You Down, Your Regulations Are Not The Problem. Your Model Is.

  Compliance friction stems from fragmented operational systems rather than regulatory standards. Unify lifecycle traceability to maintain continuous audit readiness and speed time to market.

• Regulation Is Not Slowing Your Medical Device. Your Compliance Architecture Is.

  Fragmented systems delay medical device development. Connecting lifecycle traceability into a unified compliance architecture maintains continuous audit readiness.

• 503A Vs. 503B: Turning Regulatory Complexity Into Practical Compliance

  Navigating human drug compounding requires aligning Section 503A and Section 503B operations with cGMP expectations, robust quality management systems, and standing inspection readiness.

• Continuous Readiness Is Becoming The New Operating Standard In MedTech

  Transitioning from episodic audit preparation to continuous readiness stabilizes submission timelines and aligns compliance dynamically with product development.

• Mastering QMSR: Key Takeaways And Strategies

  Harmonizing FDA regulations with ISO 13485 requires proactive quality management. Learn key strategies to streamline QMSR compliance and risk oversight.

• How AI Is Reshaping Pharmacovigilance: Key Takeaways From The New CIOMS Report

  Deploying AI in pharmacovigilance requires risk-based oversight, human accountability, transparent governance, and representative performance testing.

• Why Pharmaceutical Regulatory Compliance Software Is Essential For Biopharma Companies

  Establishing a robust, risk-based CAPA system prevents recurring process deviations, satisfies ICH Q10 guidelines, and ensures standing inspection readiness.

• The Role Of CAPA In Pharma

  Establishing a robust, risk-based CAPA system prevents recurring process deviations, satisfies ICH Q10 guidelines, and ensures standing inspection readiness.